Press releases Nektar in the news Items Per Page 102550 News Category AllFinancialGeneral Year All202620252024202320222021202020192018201720162015201420132012201120102009200820072006 Jul 28, 2026 Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets Jul 24, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 21, 2026 Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Jun 26, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 03, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 27, 2026 Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York May 07, 2026 Nektar Therapeutics Reports First Quarter 2026 Financial Results May 01, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 28, 2026 Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets Apr 23, 2026 Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares Contact IR Print Page RSS Email Alerts
Nektar in the news Items Per Page 102550 News Category AllFinancialGeneral Year All202620252024202320222021202020192018201720162015201420132012201120102009200820072006 Jul 28, 2026 Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets Jul 24, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 21, 2026 Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Jun 26, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 03, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 27, 2026 Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York May 07, 2026 Nektar Therapeutics Reports First Quarter 2026 Financial Results May 01, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 28, 2026 Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets Apr 23, 2026 Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jul 28, 2026 Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
Jul 21, 2026 Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
May 27, 2026 Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Apr 28, 2026 Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
Apr 23, 2026 Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
